Experts discuss a 3D co-culture platform for the propagation of primary multiple myeloma cells ex vivo.
Understanding preclinical modeling for cancer cells may optimize the translation of in vitro findings into clinical use, but is limited by the inability to reproducibly propagate primary specimens ex vivo. This dilemma is seen in multiple myeloma, a plasma cell disorder for which treatment significantly improved over the past several decades. Cell line models for multiple myeloma remain inefficient in predicting later clinical efficacy and the failure rate of preclinically promising anti-cancer drugs remains substantial. During this webinar, Johannes Waldschmidt, MD, and Andreas Thomsen, MD, of the University of Freiburg in Germany, will discuss a 3D co-culture platform for the propagation of primary multiple myeloma cells ex vivo.
Key Topics Include:
- How 3D models may substitute conventional testing systems
- How these models open a new framework for the in vitro assessment of drug resistance in cancer
- How they allow for more accurate prediction of active drug compounds to reduce time and financial expenses for drug discovery at the earliest stage possible
Department of Hematology & Oncology
University of Freiburg
Radiation Oncology Specialist
Department of Radiation Oncology
University Medical Center Freiburg
Co-Founder, Chief Operating Officer